"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should ...

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell ...

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...

Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly ...

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of ...

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...

The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s ...

It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...